India, Oct. 29 -- PharmEasy-backed Thyrocare's net profit for the September quarter (Q2 FY27) slumped 68.2% year-on-year (YoY) to Rs.15.2 Cr from Rs.47.8 Cr in the year-ago period. This also marks a 70% dip from Rs.51.3 Cr profit in the previous quarter.

The company's bottom line was weighed by an exceptional impairment loss of about Rs.45 Cr on its investment in radiology and diagnostic-imaging subsidiary Nueclear Healthcare Limited (NHL).

The company's board approved the sale of its entire stake in the wholly owned subsidiary to Trovera Healthcare for about Rs.141.4 Cr on September 21. The impairment costs come at the behest of the definitive term sheet for the proposed sale of the business.

"Thyrocare has issued a postal ballot seek...